From confidence to capital: Positioning biotech for the next growth cycle
China's 1H25 Innovative Drug Out-Licensing Deal Value Exceeds USD100 Billion, Hitting New High
Chinese biotech overtakes AI as emerging-market growth trade
China's Humanoid Robot Products Exceed 400 Models, Accounting for Over Half of Global Total
China's Outbound Licensing of Innovative Drugs in First Half Nears Last Year's Total
On the Eve of BIO 2026, Chinese Innovative Assets Trigger a New Wave of Global Collaborations